Moving beyond the topic, Companion Diagnostics in Targeted Treatment, the panel took on the unregulated nature of testing in the wake of the June 2013 US Supreme Court ruling against Myriad Genetics, which ended the company's BRCA testing monopoly.
Michael A. Kolodziej, MD
Advertisement
Articles by Michael A. Kolodziej, MD
A lively discussion on Foundation Medicine's approach to creating genomic profiles.
Advertisement
Latest Updated Articles
- Next-Generation Sequencing in Oncology: Are We Ready for Prime Time?
January 29th 2014
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies
5